Skip to Navigation Skip to Search Skip to Content
Search All Centers

New Drug Approval for CLL: An Expert Explains How the Treatment Landscape is Evolving

Read Transcript Download/Print Transcript

Published on November 14, 2018

During this Ask the Expert segment, a Patient Power community member wants to know, “where does the new drug, duvelisib, fit into the chronic lymphocytic leukemia (CLL) treatment landscape?” CLL expert Dr. Jeff Sharman, from The US Oncology Network, responds by explaining how the recently approved medicine works, which drug class it fits into and when it’s appropriate to use in a clinical setting. Watch now to learn more.

This is a Patient Empowerment Network program produced by Patient Power. We thank AbbVie, Inc. and Pharmacyclics for their support. These organizations have no editorial control. Patient Power is solely responsible for program content.

Featuring

You might also like

Transcript | New Drug Approvals for CLL: An Expert Explains How the Treatment Landscape Is Evolving

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That's how you’ll get care that's most appropriate for you.

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.

Andrew Schorr:

Here's a question that came in based on news events that people follow related to CLL, and this is from William.  He says, I heard there's a new drug approved for CLL, duvelisib.  Can you tell more about this?  Where does it fit in in the CLL landscape?  

It is a—the drug class is a sort of the whole PI3 family of which there's a growing number.  There's idelalisib, umbralisib is in late-stage clinical trials.  Copanlisib (Aliqopa) is approved in follicular lymphoma but not CLL.  And as a family they tend to be utilized less frequently than the BTK inhibitors such as ibrutinib and to some degree less frequently than venetoclax (Venclexta), as well, the Bcl-2 family, and that has to do with some of the side effects, that there is, a frequency of diarrhea, LFT abnormalities and so forth.  So it follows on the heels of idelalisib, and I would say has more similarities than differences.  

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.

You might also like